BioHealth News
Federal Trade Commission allows Amgen’s $27.8 billion acquisition of Horizon Therapeutics
THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves…
Read More
5 Excellent Finalists Chosen for the 8th Annual BHCR Crab Trap
Rockville, Maryland – September 13, 2023 – BioHealth Innovation, Inc. (BHI), a leading regional innovation intermediary, is thrilled to announce the five outstanding finalists…
Read More
Accelerate Investor Conference Returns to Showcase Leading Early-Stage Companies to National Investors
ARLINGTON, Va.--(BUSINESS WIRE)--The Accelerate Investor Conference is back for its third year at George Mason University’s Arlington Campus, November 1-2, 2023. Spurring the region’s innovation…
Read More
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and…
Read More
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject…
Read More
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat…
Read More
Rockville’s Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
ROCKVILLE, Md., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the…
Read More
REGISTER NOW – The 9th Annual BioHealth Capital Region Forum: A Week Away and a World of Opportunity
One week away from the 9th Annual BioHealth Capital Region Forum (https://bit.ly/BHCRForum2023), a cornerstone event for anyone involved in the biopharma sector. Scheduled for…
Read More
Adaptive Phage Therapeutics CEO Greg Merril and His Father’s Journey Highlighted in BBC StoryWorks’ Documentary, ‘Race Against Resistance’
The documentary-style film addresses the urgent global health crisis of antimicrobial resistance, which is causing widespread concern in the scientific and medical fields. The…
Read More
Seize Opportunities at the 6th Annual BioHealth Capital Region Investment Conference: Applications Due September 12th
Your Invitation to apply to a Key Investment Event in Rockville, Maryland Awaits There's still time if you haven't yet marked your calendar for…
Read More
Still Time to Register: Unlock Collaboration at the 9th Annual BioHealth Capital Region Forum
Your Invitation to a Pivotal BioHealth Event in Rockville, Maryland Awaits If you haven't yet marked your calendar for the 9th Annual BioHealth Capital…
Read More
BIO Podcast Episode 87: The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab?
The horseshoe crab has endured for over 450 million years.In this episode we talk with three experts about how this animal’s unique blue blood…
Read More
PM Live: GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch
GSK has announced it is investing over £270m to build a new vaccine manufacturing facility at its Wavre campus in Belgium. The investment follows…
Read More
VLP Therapeutics group announces 2nd closing of funding to develop cancer, infectious disease vaccines, establish investigational vaccine manufacturing facility
US-based biotech company VLP Therapeutics, Inc. (VLPT) and its Tokyo-based group company VLP Therapeutics Japan, Inc. (VLPT Japan) together announced on September 5 the…
Read More
Rockville’s MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics…
Read More